Non-interventional study to evaluate the effect of antidiabetic drug dosing in type-2 diabetes patients with abnormal BMI compared with Type-2 diabetes patients with normal BMI

• Author Details:   
• Kanikella Sivaji
• Nallajerla Sai Krishna
• Ramanakula Rupakalpana Swathimala
• Gajja Venkata Bharath
• Chalamala Syam Kumar
• Kummari Sai Kuma

Introduction: Type-2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. It is one of the most prevalent non-communicable diseases globally and is associated with significant morbidity and mortality. Management of T2DM typically involves lifestyle modifications, including dietary changes and exercise, alongside pharmacological interventions such as oral hypoglycaemic agents and insulin therapy.

Aims & Objectives: To assess the effect of antidiabetic drug dose on glycemic control and clinical outcomes in type 2 diabetes mellitus (T2DM) patients with abnormal body mass index (BMI) vs those with normal BMI in a real-world clinical setting.

Materials and Methods: This research will use data from electronic health records (EHRs) in a retrospective cohort design. Since the study is non-interventional, no adjustments will be made to patient care or treatment as a result of its findings. Data from current clinical records will be gathered in the past.

Results: The study comprised 500 T2DM patients, 70% of whom were normal weight, 30% of whom were overweight, and 30% of whom were obese. Individuals in the normal weight group (7.5% ± 0.9, p < 0.001) had a baseline HbA1c that was considerably lower than those in the obese group (8.2% ± 1.2). The percentage of obese patients who attained HbA1c < 7% (35%) after 6 months was lower than that of patients of normal weight (50%, p = 0.02). The group with obesity received an average of 80 units of antidiabetic medicine per day, which was considerably greater than the group with normal weight (60 units, p < 0.001).

Conclusion: Type-2 diabetes patients with abnormal BMI (overweight or obese) demonstrated moderate glycemic control but required higher doses of antidiabetic medications, reflecting the typical insulin resistance associated with obesity.